MarginsXMarginsX
Home › Markets › Health Care › IBO

Impact BioMedical Inc. (IBO)

IBO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.91
-4.47% on the day
Market cap
$42.4M
Nano cap
Revenue · 2025
$32K
Prior year not contiguous
Net income · 2025
-$11.8M
-36993.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1834105/000149315226009711/0001493152-26-009711-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIBO on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNot reported by the screener
IPO year2024
SEC CIK0001834105
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2025

LineValue
Revenue$32K
Net income-$11.8M
Operating income-$4.3M
Net margin-36993.8%
Operating margin-13381.3%
Revenue growthNo prior-year revenue to compare
Cash$3K
Total assets$17.4M
P/E (computed)Net income was not positive
P/S (computed)1325.7×

Warning signs

Cash runway
Cash-flow positive
$21K cash at September 30, 2026
Share count, 1 year
+4.5%
2025-10-27 to 2026-11-05 · +993.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
-$59K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued."
10-Q 2026-11-09
Cash and burn$21K cash; operating cash flow $29K a quarter.Report 2026-09-30
Shares outstanding8,640,000 (2026-11-05); 104,621,231 a year earlier; 10,000,000 three years earlier. 1y figure adjusted for split (1-for-12.658 overall); 3y figure adjusted for split (1-for-12.658 overall).Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-12.658 on 2026-09-23Source 2026-09-23
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrassi & Co., CPAs, P.C., Jericho, New York, United StatesPCAOB Form AP 2026-03-16
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $59K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$21K-$645K$11K$21KNo debt tags$38K10-Q 2026-11-09
Q2 2026
2026-06-30
$3K-$699K$470K$10KNo debt tags$35K10-Q 2026-08-07
Q1 2026
2026-03-31
$7K-$2.3M-$464K$20KNo debt tags$39K10-Q 2026-05-12
Q4 2025
2025-12-31
$7K$5.2M$99K$3KNo debt tags$32K10-K 2026-03-11
Q3 2025
2025-09-30
$18K-$1.5M-$613K$12K$22.9MNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
$7K-$14.3M-$694K$624K$22.4MNeeds four quarters10-Q 2026-08-07
Q1 2025
2025-03-31
Not filed-$1.3M-$682K$1.3M$9.1MNeeds four quarters10-Q 2026-05-12
Q4 2024
2024-12-31
Not filed-$27.1M-$986K$2.0M$21.0MNeeds four quarters10-K 2026-03-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42024-09-17
Latest annual report10-K2026-03-11
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-03
Latest proxyDEFM14A2026-10-27

Source: SEC EDGAR submissions feed, 156 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+25.4%
1 month+29.1%
3 months-7.7%
Year to date-19.6%
1 year-20.4%
From 52-week high-47.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ELTXElicio Therapeutics Inc.$1.48-1.33%$41.9M
PLRXPliant Therapeutics Inc.$0.6932-0.55%$43.0M
GANXGain Therapeutics Inc.$0.9402-9.60%$41.9M
DWTXDogwood Therapeutics Inc.$1.06-8.62%$40.5M
CNTBConnect Biopharma Holdings Limited$0.6430-5.05%$40.5M
ALDXAldeyra Therapeutics Inc.$0.6696+4.01%$40.4M
ONCYOncolytics Biotech Inc.$0.3399-8.14%$44.6M
HYFTMindWalk Holdings Corp.$0.9378-8.95%$44.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier